Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DateTimeSourceHeadlineSymbolCompany
08/11/202210:01AMGlobeNewswire Inc.ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer FoxNASDAQ:KYMRKymera Therapeutics Inc
08/10/202212:35PMTipRanksKymera Therapeutics (KYMR) Gets a Buy from Credit SuisseNASDAQ:KYMRKymera Therapeutics Inc
08/10/20226:20AMTipRanksAnalysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Apellis Pharmaceuticals (APLS)NASDAQ:KYMRKymera Therapeutics Inc
08/09/20223:45PMTipRanksBrookline Capital Markets Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)NASDAQ:KYMRKymera Therapeutics Inc
08/09/20227:17AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KYMRKymera Therapeutics Inc
08/09/20227:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
07/27/20227:30AMGlobeNewswire Inc.Kymera Therapeutics to Report Second Quarter 2022 Results on August 9NASDAQ:KYMRKymera Therapeutics Inc
07/11/20222:11PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KYMRKymera Therapeutics Inc
07/08/20224:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
07/08/20224:06PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:KYMRKymera Therapeutics Inc
07/08/20227:45AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KYMRKymera Therapeutics Inc
07/08/20227:30AMGlobeNewswire Inc.Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh MorganNASDAQ:KYMRKymera Therapeutics Inc
07/01/20224:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/21/20226:45AMTipRanksBrookline Capital Markets Thinks Kymera Therapeutics’ Stock is Going to RecoverNASDAQ:KYMRKymera Therapeutics Inc
06/17/20227:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:06PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/16/20224:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
06/15/20227:00AMPR Newswire (US)Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413NASDAQ:KYMRKymera Therapeutics Inc
06/01/20225:01PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:KYMRKymera Therapeutics Inc
06/01/20229:35AMDow Jones NewsKymera Therapeutics Gets Orphan Drug Designation for KT-333 Lymphoma TreatmentNASDAQ:KYMRKymera Therapeutics Inc
06/01/20228:42AMGlobeNewswire Inc.Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell LymphomaNASDAQ:KYMRKymera Therapeutics Inc
06/01/20228:34AMTipRanksWells Fargo Thinks Kymera Therapeutics’ Stock is Going to RecoverNASDAQ:KYMRKymera Therapeutics Inc
06/01/20228:17AMTipRanksKymera Therapeutics: Dosed Up on High Insider BuyingNASDAQ:KYMRKymera Therapeutics Inc
06/01/20227:00AMGlobeNewswire Inc.Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid ArthritisNASDAQ:KYMRKymera Therapeutics Inc
05/31/20227:50PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

Your Recent History

Delayed Upgrade Clock